Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1983 1
1984 3
1991 1
1992 1
1993 2
1994 1
1996 1
1998 1
2002 3
2003 1
2004 2
2005 2
2006 5
2007 16
2008 16
2009 18
2010 28
2011 27
2012 28
2013 25
2014 32
2015 21
2016 9
2017 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacogenetics of antiretroviral therapy.
Barreiro P, Fernández-Montero JV, de Mendoza C, Labarga P, Soriano V. Barreiro P, et al. Among authors: labarga p. Expert Opin Drug Metab Toxicol. 2014 Aug;10(8):1119-30. doi: 10.1517/17425255.2014.930128. Epub 2014 Jun 18. Expert Opin Drug Metab Toxicol. 2014. PMID: 24941049 Review.
Dual antiretroviral therapy for HIV infection.
Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, Mendoza C, Arias A, Barreiro P, Peña JM, Labarga P. Soriano V, et al. Among authors: labarga p. Expert Opin Drug Saf. 2017 Aug;16(8):923-932. doi: 10.1080/14740338.2017.1343300. Epub 2017 Jul 11. Expert Opin Drug Saf. 2017. PMID: 28621159 Review.
Update on HIV/HCV coinfection.
Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P. Soriano V, et al. Among authors: labarga p. Curr HIV/AIDS Rep. 2013 Sep;10(3):226-34. doi: 10.1007/s11904-013-0169-5. Curr HIV/AIDS Rep. 2013. PMID: 23832718 Review.
Pharmacogenetics of tenofovir treatment.
Rodriguez-Novoa S, Labarga P, Soriano V. Rodriguez-Novoa S, et al. Among authors: labarga p. Pharmacogenomics. 2009 Oct;10(10):1675-85. doi: 10.2217/pgs.09.115. Pharmacogenomics. 2009. PMID: 19842939 Review.
Hepatitis C cure with antiviral therapy--benefits beyond the liver.
Soriano V, Labarga P, Fernandez-Montero JV, de Mendoza C, Esposito I, Benítez-Gutiérrez L, Barreiro P. Soriano V, et al. Among authors: labarga p. Antivir Ther. 2016;21(1):1-8. doi: 10.3851/IMP2975. Epub 2015 Jun 25. Antivir Ther. 2016. PMID: 26110692 Review.
Renal toxicity associated with tenofovir use.
Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V. Rodriguez-Nóvoa S, et al. Among authors: labarga p. Expert Opin Drug Saf. 2010 Jul;9(4):545-59. doi: 10.1517/14740331003627458. Expert Opin Drug Saf. 2010. PMID: 20384533 Review.
[Reproductive advice in HIV-discordant couples].
Labarga P, Martínez E, Soriano V, Barreiro P. Labarga P, et al. Med Clin (Barc). 2007 Jun 23;129(4):140-8. doi: 10.1157/13107489. Med Clin (Barc). 2007. PMID: 17663969 Review. Spanish. No abstract available.
Dolutegravir, abacavir and lamivudine as HIV therapy.
Fernandez-Montero JV, Barreiro P, Labarga P, De Mendoza C, Soriano V. Fernandez-Montero JV, et al. Among authors: labarga p. Expert Opin Pharmacother. 2014 May;15(7):1051-7. doi: 10.1517/14656566.2014.913023. Expert Opin Pharmacother. 2014. PMID: 24754315 Review.
Drug interactions with new hepatitis C oral drugs.
Soriano V, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Esposito I, Benítez-Gutiérrez L, Peña JM. Soriano V, et al. Among authors: labarga p. Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):333-41. doi: 10.1517/17425255.2015.998997. Epub 2015 Jan 2. Expert Opin Drug Metab Toxicol. 2015. PMID: 25553890 Review.
222 results